| Document |
Document Title |
|
WO/2021/046628A1 |
A stable medicinal cannabidiol composition for use in oral delivery, the composition comprising synthetic cannabidiol (CBD) having a purity of at least 99.8 %, preferably at least 99.9 %, together with beta-caryophyllene (BCP) which func...
|
|
WO/2021/047491A1 |
The present invention relates to a method for simultaneously separating cannabidivarin and cannabigerol, comprising: sufficiently oscillating a solvent system, allowing the solvent system to stand, and separately collecting an upper phas...
|
|
WO/2021/046640A1 |
The present disclosure relates to new cannabinoid derivatives and precursors and catalytic asymmetric processes for their preparation. The disclosure also relates to pharmaceutical compositions and pharmaceutical and analytical uses of t...
|
|
WO/2021/049294A1 |
Provided is a 1,1'-Bi-2-naphthol powder in which particles do not easily agglomerate during storage. A 1,1'-Bi-2-naphthol powder powder according to an embodiment of the present invention has a frequency distribution, obtained by dry par...
|
|
WO/2021/049293A1 |
Provided is a method for producing a 1-1'-bi-2-naphthol compound of good color. A method for producing a 1-1'-bi-2-naphthol compound, according to an embodiment of the present invention, includes a step of obtaining a 1-1'-bi-2-naphthol ...
|
|
WO/2021/046636A1 |
The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.
|
|
WO/2021/042721A1 |
Disclosed is a method for preparing m-trifluoromethylphenol. The present invention provides a method for preparing m-trifluoromethylphenol, which comprises the following steps: step (1): in a continuous flow reactor, subjecting an aqueou...
|
|
WO/2021/035344A1 |
Disclosed herein is a method for upgrading a cannabinoid mixture that comprises tetrahydrocannabinol (THC) and one or more non-THC cannabinoids, when the cannabinoid mixture has a THC content of less than about 20 wt. %. The method compr...
|
|
WO/2021/041506A1 |
Naphthoquinone derivatives of Lawsone have been found to be effective against Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA). Such compounds generally contain a substituent group at the 3-position of a speci...
|
|
WO/2021/030913A1 |
The present disclosure relates to cannabinoid compositions that are rehydratable and that upon such rehydration retain at least some of the properties of the original cannabinoid emulsions from which the cannabinoid composition was obtai...
|
|
WO/2021/030690A2 |
Disclosed herein are systems and methods of depolymerizing a lignin component of a lignin-containing material. The method comprising contacting the lignin-containing material with a solvent and optionally a catalyst at a temperature in t...
|
|
WO/2021/029395A1 |
A compound which has one or more halogen atoms and an unsaturated double bond. A method for producing an iodine-containing vinyl monomer, said method comprising: (a) a step for preparing an iodine-containing alcoholic substrate having a ...
|
|
WO/2021/022469A1 |
The present invention provides a continuous synthesis-purification integrated device and a continuous reaction system containing the same. The continuous synthesis-purification integrated device comprises: a reaction section, a purificat...
|
|
WO/2021/016717A1 |
The present disclosure relates to isolating one or more cannabinoids from an input mixture. There is disclosed an apparatus that comprises a mixing vessel, a volatizing unit, and a distillation unit. The mixing vessel combines a first in...
|
|
WO/2021/016716A1 |
The present disclosure relates to isolating one or more cannabinoids from an input mixture. There is disclosed an apparatus that comprises a first reaction vessel, a volatizing unit, and a distillation unit. The first reaction vessel pro...
|
|
WO/2021/016987A1 |
A pharmaceutical compound TG1 (2, 3, 5, 4'-tetrahydroxy-trans-stilbene) and a new use for treating colorectal cancer thereofare provided. The pharmaceutical compound has the structure of formula I. Each variable in formula I and treating...
|
|
WO/2021/016718A1 |
The present disclosure relates to isolating one or more cannabinoids from an input mixture. There is disclosed an apparatus that comprises a volatizing unit, a fractional distillation unit, and a condensing unit. The volatizing unit rece...
|
|
WO/2021/012046A1 |
There are provided compositions comprising at least one compound chosenfrom compound of formula (I), compound of formula (II), compound of formula (III) and compound of formula (IV) and a cannabinoid extract.
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2021/001044A1 |
Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of Eltrombopag, passing through/using intermediate 5'-Chloro-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid alkaline metal sal...
|
|
WO/2020/252588A1 |
Grafted cannabis plants and related methods for producing a grafted cannabis plant are provided. In some embodiments, a scion is provided from a first cannabis plant having at least one of a first desired phenotype and a first desired ge...
|
|
WO/2020/257234A1 |
A process for isolation of bisphenol A from depolymerization of a poly(carbonate) includes depolymerizing a poly(carbonate) having repeating units derived from bisphenol A in the presence of a base, a Ci-6 alcohol, and an organic cosolve...
|
|
WO/2020/257237A1 |
A process for depolymerization of poly(carbonate) includes combining a poly(carbonate) including repeating units derived from bisphenol A; bisphenol A; water; and a base under conditions effective to depolymerize the poly (carbonate). A ...
|
|
WO/2020/248060A1 |
Disclosed herein is a method for converting cannabidiol (CBD) into a composition comprising Δ9-tetrahydrocannabinol (Δ9-THC) and Δ8-tetrahydrocannabinol (Δ8-THC) in which the composition has a Δ9-ΤΗC:Δ8-ΤΗC ratio of greater tha...
|
|
WO/2020/249184A1 |
The present invention relates to a method for producing cannabigerol and purifying it from a reaction mixture. The present invention also relates to the cosmetic use of cannabigerol for the inhibition of tyrosinase activity and/or the re...
|
|
WO/2020/248058A1 |
Disclosed herein a method for converting (cannabidiol) CBD into a composition comprising Δ8-tetrahydrocannabinol (A8-THC) and Δ9-tetrahydrocannabinol (Δ9-THC), in which the composition has a Δ8-THC:Δ9-THC ratio that is greater than ...
|
|
WO/2020/248062A1 |
Disclosed herein is a method for converting a first cannabinoid into a composition comprising a second cannabinoid and a third cannabinoid, in which the second cannabinoid and the third cannabinoid are each isomers of the first cannabino...
|
|
WO/2020/252369A1 |
The application relates to crystalline cannabigerol comprising at least one X-ray powder diffraction peak selected from the group consisting of 4.73°, 9.52°, 14.30°, and 23.93° 2Θ (each ± 0.20° 2Θ), to methods of making the cryst...
|
|
WO/2020/248071A1 |
A method and system for isolating trichomes from plant matter. The method and system are applied to biomass including trichomes bound to structural plant material. The biomass is combined with a solution including a chelating agent for l...
|
|
WO/2020/248059A1 |
Disclosed is a method for converting a first cannabinoid into a second cannabinoid that is a regioisomer of the first cannabinoid. The method comprising contacting the first cannabinoid with: (i) a base having a pKb that is less than a c...
|
|
WO/2020/248061A1 |
Disclosed herein is a method for converting cannabidiol (CBD) into a composition comprising Δ9-tetrahydrocannabinol ( Δ9-THC) and Δ8-tetrahydrocannabinol ( Δ8-THC) in which the composition has a Δ9-ΤΗΟ: Δ8-ΤΗΟ ratio of greate...
|
|
WO/2020/243844A1 |
The present disclosure relates to a cannabinoid composition that has enhanced absorption rates or higher concentrations of the administered cannabinoid into the systemic circulation, the composition comprising at least one cannabinoid an...
|
|
WO/2020/237806A1 |
The present invention relates to the field of organic synthesis. Provided is a preparation method for 4-fluorine-3-methoxyl-5-methylaniline hydrochloride. A synthetic route of the preparation method for 4-fluorine-3-methoxyl-5-methylanil...
|
|
WO/2020/243588A1 |
The present disclosure relates to the preparation of halogenated dihydroxybenzene compounds with high yield, selectivity and purity. The compounds are useful, among other things, in the synthesis of cannabinoids and cannabinoid-type comp...
|
|
WO/2020/237388A1 |
A formulation for solubilizing a water insoluble pharmaceutical agent is provided. The formulation comprises: a water-insoluble pharmaceutical agent, a detergent, an enzyme that breaks down lipids, proteins, and/or starches, a plasticizi...
|
|
WO/2020/232545A1 |
The present disclosure relates to new cannabinoid sulfonate esters and processes for their use to prepare cannabinoids. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabinoids from ...
|
|
WO/2020/232557A1 |
The present technology generally relates to methods of making cocoa butter-derived products that comprise cannabinoids. The present technology further generally relates to cocoa butter-derived products resulting from such methods.
|
|
WO/2020/232530A1 |
There are provided compositions comprising a purified cannabidiol (CBD) or a derivative thereof and an anti-inflammatory botanical extract, and methods of use thereof for the management of pain in a subject.
|
|
WO/2020/234650A1 |
A composition comprising an active composition made up of at least 5% CBD, at least 2% β-caryophyllene, and at least 2% linalool; wherein said composition comprises a carrier and excipients to increase oral bioavailability for mammalian...
|
|
WO/2020/233502A1 |
Disclosed is a method for preparing cannabidiol and analogues thereof; the method is implemented by means of reacting a resorcinol derivative with menthyl-2,8-dien-1-ol or a derivative thereof. The method of the present invention has adv...
|
|
WO/2020/229891A1 |
Methods of manufacturing cannabidiol (CBD) and cannabidivarin (CBDV); intermediates of the methods of manufacturing CBD and CBDV; and crystallized CBD and CBDV obtained via described methods.
|
|
WO/2020/227830A1 |
Methods for extracting one or more chemical compounds from cannabis plant material are provided. In some embodiments, the method may comprise: providing the cannabis plant material; extracting the cannabis plant material with a solvent t...
|
|
WO/2020/223811A1 |
Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or...
|
|
WO/2020/223800A1 |
A formulation for pain management is described for use by individuals experiencing pain. The formulation comprises a plurality of cannabinoids in optimized amounts to manage pain. One or more excipient, diluent or carrier is included in ...
|
|
WO/2020/226126A1 |
A compound having a fluorene skeleton represented by formula (1), which is characterized in that a resin obtained by using this compound having a fluorene skeleton as a starting material is excellent in terms of various characteristics (...
|
|
WO/2020/220852A1 |
The present invention relates to the technical field of medicine, and particularly relates to a preparation method for cannabidiol (CBD). The preparation method of the present invention comprises the steps of extraction, decarboxylation,...
|
|
WO/2020/220141A1 |
Transdermal cannabinoid formulations comprising a versatile cannabinoid stock provided as a variety of cosmetic delivery systems providing enhanced cannabinoid absorption, and more controlled release into vascular and/or lymphatic system...
|
|
WO/2020/217209A1 |
The invention provides a method for depolymerising a phenolic polymer, the method comprising reacting the phenolic polymer with dimethylsulphoxide (DMSO) and a hydrogen halide. The phenolic polymer may be selected from the group consisti...
|
|
WO/2020/214574A1 |
Herein are described apparatus and processes for the preparation of cannabinoids, such as cannabidiol (CBD) and derivatives thereof. The apparatus and processes described can be used for the one-step, flow-mediated synthesis of cannabidi...
|
|
WO/2020/215006A1 |
Provided herein are novel antibacterial compounds of Formula (I). The compounds can be made through enzymatic oxidative dimerization in the presence of a suitable organism and one or more metal salts. Pathogenic bacteria exposed to the c...
|
